Pfizer Corporation

Requalia Pharma Inc.

Kana Kon-I

Chikara Uchida

Hirohide Noguchi

Yasuhiro Katsu

Hiroki Koike

Kazuo Ando

Yoshiyuki Okumura

Tatsuya Yamagishi

Kazunari Nakao

Mikio Morita

Tomoki Kato

Satoru Iguchi

Miyako Matsumizu

Yukari Matsumoto

Yohei Yuki

Akiko Shima

This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein A, R, R, R, R, R, m and n are each as described herein, and compositions containing such compounds, and the use of such compounds in the treatment of a condition mediated by CB2 receptor activity such as, but not limited to, inflammatory pain, nociceptive pain, neuropathic pain, fibromyalgia, chronic low back pain, visceral pain, acute cerebral ischemia, pain, chronic pain, acute pain, post herpetic neuralgia, neuropathies, neuralgia, diabetic neuropathy, HIV-related neuropathy, nerve injury, rheumatoid arthritic pain, osteoarthritic pain, back pain, cancer pain, dental pain, fibromyalgia, neuritis, sciatica, inflammation, neurodegenerative disease, cough, broncho constriction, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colitis, cerebrovascular ischemia, emesis such as cancer chemotherapy-induced emesis, rheumatoid arthritis, asthma, Crohn's disease, ulcerative colitis, asthma, dermatitis, seasonal allergic rhinitis, GERD, constipation, diarrhea, functional gastrointestinal disorders, irritable bowel syndrome, cutaneous T cell lymphoma, multiple sclerosis, osteoarthritis, psoriasis, systemic lupus erythematosus, diabetes, glaucoma, osteoporosis, glomerulonephritis, renal ischemia, nephritis, hepatitis, cerebral stroke, vasculitis, myocardial infarction, cerebral ischemia, reversible airway obstruction, adult respiratory disease syndrome, COPD, cryptogenic fibrosing alveolitis and bronchitis. 

Sulfonyl benzimidazole derivatives

This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein A, B, R, Rand Rare each as described herein, and compositions containing such compounds, and the use of such compounds in the treatment of a condition mediated by CB2 receptor activity.

This invention provides a compound of the formula (I): wherein

Substituted methyl aryl or heteroaryl amide compounds

This invention provides a compound of the formula (I):or a pharmaceutically acceptable salt thereof, wherein These compounds have 5-HTreceptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.

[object Object]

This invention provides a compound of the formula (I):or a pharmaceutically acceptable salt, amide or ester thereof, wherein Rrepresents a hydrogen atom or a halogen atom; Rrepresents a hydrogen atom, etc.; Rrepresents an alkyl group having from 1 to 10 carbon atoms; said alkyl group of Ris substituted by at least one substituent selected from the group consisting of substituents &#x3b1;; said substituents &#x3b1; is aryl, hydroxy, oxo, etc.; said aryl having 6 to 10 carbon atoms; said aryl is unsubstituted or substituted by at least one alkyl group having from 1 to 6 carbon atoms; said heterocyclic and the heterocyclic moiety of said heterocycliccarbonyl, both of substituents &#x3b1;, are 5- to 10-membered cyclic groups containing from 1 to 4 heteroatoms selected from the group consisting of nitrogen atoms, oxygen atoms and sulfur atoms These compounds have 5-HTreceptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.

N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators

Growing community of inventors

Chita-gun, Japan

Kana Kon-I